- Barth RF, Soloway AH, Goodman JH, et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999; 44: 433-51.
- Shih JL, Brugger RM. Gadolinium as a neutron capture therapy agent. Med Phys 1992; 19: 733-44.
- De Rosa FS, Bentley MV. Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res 2000; 17: 1447-55.
- Liu FF, Wilson BC. Hyperthermia and photodynamic therapy. In: Tannock IF, 5. Hill RP, eds. Basic science of oncol-ogy. New York: McGraw-Hill Publisher; 1998. p. 453-465.
- Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photody-namic therapy in oncology. Expert Opin Pharmacother 2001; 2: 917-27.
- Hartman T, Carlsson J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother Oncol 1994; 31: 61-75.
- Coderre JA, Gavin PR, Capala J, et al. Tolerance of the normal canine brain to epithermal neutron irradiation in the presence of p-boronophenylalanine. J Neurooncol 2000; 48: 27-40.
- Gavin PR, Kraft SL, Huiskamp R, Coderre JA. A review: CNS effects and normal tissue tolerance in dogs. J Neuroon-col 1997; 33: 71-80.
- Sweet WH. Early history of development of boron neutron capture therapy of tumors. J Neurooncol 1997; 33: 19-26.
- Nakagawa Y, Hatanaka H. Boron neutron capture therapy: clinical brain tumour studies. J Neurooncol 1997; 33: 105-15.
- Hatanaka H, Nakagawa Y. Clinical results of long-surviving brain tumour patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 1994; 28: 1061-6.
- Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Ra-diat Oncol Biol Phys 2000; 47: 209-18.
- Chanana AD, Capala J, Chadha M, et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 1999; 44: 1182-93.
- Aziz T, Press NS, Diaz AZ, et al. Postmortem neuropatholog-ical features secondary to boron neutron capture therapy for glioblastom multiforme. J Neuropathol Exp Neurol 2000; 50: 62-73.
- Rassow J, Stecher-Rasmussen F, Voorbraak W, et al. Com-parison of quality assurance for performance and safety char-acteristics of the facility for boron neutron capture therapy in Petten/NL with medical electron accelerators. Radiother Oncol 2001; 59: 99-108.
- Diaz AZ, Coderre JA, Chanana AD, Ma R. Boron neutron capture therapy for malignant gliomas. Ann Med 2000; 32: 81-5.
- Fukuda H, Honda C, Wadabayashi N, et al. Pharmacokinet-ics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res 1999; 9: 75-83.
- Laramore GE. The use of neutrons in cancer therapy: a historical perspective through the modern era. Semin Oncol 1997; 24: 672-85.
- Tjarks W, Wang J, Chandra S, et al. Synthesis and biological evaluation of boronated nucleosides for boron neutron capture therapy (BNCT) of cancer. Nucleosides Nucleotides Nu-cleic Acids 2001; 20: 695-8.
- Ceberg CP, Brun A, Kahl SB, et al. A comparative study on the pharmacokinetics and biodistribution of boronated por-phyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J Neurosurg 1995; 83: 86-92.
- Gedda L, Ghaneolhosseini H, Nilsso n P, et al. The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids. Anticancer Drug Des 2000; 15: 277-86.
- Hawthorne MF. New horizons for therapy based on the boron neutron capture reaction. MoI Med Today 1998; 4: 174-81.
- Sjoberg S, Carlsson J, Ghaneolhosseini H, et al. Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. J Neurooncol 1997; 33: 41-52.
- Carlsson J, Gedda L, Grönvik C, et al. Strategy for boron neutron capture therapy against tumor cells with over-expres-sion of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys 1994; 30: 105-15.
- Barth RF, Adams DM, Soloway AH, et al. Boronated star-burst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem 1994; 5: 58-66.
- Capala J, Barth RF, Bendayan M, et al. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 1996; 7: 7-15.
- Nakanishi A, Guan L, Kane RR, et al. Toward a cancer therapy with boron-rich oligomeric phosphate diesters that target the cell nucleus. Proc Natl Acad Sei USA 1999; 96: 238-41.
- Munck af Rosenschold PM, Verbakel WF, Ceberg CP, et al. Toward clinical application of prompt gamma spectroscopy for in vivo monitoring of boron uptake in boron neutron capture therapy. Med Phys 2001; 28: 787-95.
- Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res 1999; 151: 1-18.
- Moss RL, Aizawa O, Beynon D, et al. The requirements and development of neutron beams for neutron capture therapy of brain cancer. J Neurooncol 1997; 33: 27-40.
- Alien DA, Beynon TD, Green S. Design for an accelerator-based orthogonal epithermal neutron beam for boron neutron capture therapy. Med Phys 1999; 26: 71-6.
- Morris GM, Micca PL, Rezvani M, et al. Boron neutron capture therapy: effects of split dose and overall treatment time. J Neurooncol 2001; 52: 101-10.
Acta Oncologica
Volume 41, 2002 - Issue 7-8